Clinical Trial Update: Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating polyethylene glycol liposome doxorubicin (PLD) for primary lymphoma (including Non-Hodgkin and Hodgkin lymphoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Polyethylene glycol liposome doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Shandong Provincial Hospital | Conditions: Lymphoma, Non-Hodgkin;Hodgkin Disease | Phase 4 | Status: UNKNOWN